AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30427588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin/Sitagliptin FDC (15-100 mg)
Number of subjects: 14
Study 30427588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin/Metformin FDC (7.5-1000 mg)
Number of subjects: 14
Study 30427588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin monotherapy and FDCs
Number of subjects: 14
Study 30427588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin and ertugliflozin/Sitagliptin FDC
Number of subjects: 14
Study 30427588 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertugliflozin/Metformin FDC
Number of subjects: 14
Study 28243359 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% BPC‐350
Number of subjects: 11
Study 28243359 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% BPC‐350
Number of subjects: 11
Study 28243359 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% BPC‐350 (in Meal 2 and 3)
Number of subjects: 11
Study 26431906 — intervention group
Group type: EXPERIMENTAL
Intervention: ARA290 (2 mg)
Number of subjects: 36
Study 26431906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 24267254 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-therapy with simvastatin (40 mg daily), extended-release niacin (1500 mg daily), and ezetimibe (10 mg daily)
Number of subjects: 102
Study 24267254 — intervention group
Group type: COMPARATOR
Intervention: Mono-therapy with simvastatin (40 mg daily)
Number of subjects: 102
Study 20727626 — intervention group
Group type: EXPERIMENTAL
Intervention: New fortifier (NF)
Number of subjects: 30
Study 20727626 — intervention group
Group type: COMPARATOR
Intervention: Standard fortifier (SF)
Number of subjects: 30
Study 20727626 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformulated fortifier (RF)
Number of subjects: 30
Study 20727626 — intervention group
Group type: EXPERIMENTAL
Intervention: All infants studied with MA
Number of subjects: 30
Study 19723123 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonabersat, a gap-junction modulator, well tolerated, no cardiovascular effects, pharmacokinetic profile suggests usefulness in migraine prophylaxis.
Number of subjects: 0
Study 19723123 — intervention group
Group type: COMPARATOR
Intervention: Antiepileptic drugs and beta-blockers, commonly used preventive therapies, mechanisms of action unknown.
Number of subjects: 0
Study 15217131 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal administration of 15 ml 2% Lidocaïne gel
Number of subjects: 308
Study 15217131 — intervention group
Group type: COMPARATOR
Intervention: Lidocaïne periprostatic infiltration (10 ml of 1% Lidocaïne in two injections)
Number of subjects: 308
Study 10602355 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat wood stanol ester margarine (WSEM)
Number of subjects: 60
Study 10602355 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable oil stanol ester margarine (VOSEM)
Number of subjects: 60
Study 10602355 — intervention group
Group type: COMPARATOR
Intervention: Control (no stanol esters) margarine
Number of subjects: 60
Study 7863993 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 and 100 mg/day)
Number of subjects: 15
Study 7863993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1645332 — intervention group
Group type: EXPERIMENTAL
Intervention: BV-araU 150 mg/day
Number of subjects: 0
Study 1645332 — intervention group
Group type: EXPERIMENTAL
Intervention: BV-araU 30 mg/day
Number of subjects: 0
Study 1645332 — intervention group
Group type: COMPARATOR
Intervention: Both doses of BV-araU
Number of subjects: 0
Study 1645332 — intervention group
Group type: EXPERIMENTAL
Intervention: BV-araU (both doses)
Number of subjects: 0
Study 6789665 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-solution regimen
Number of subjects: 18
Study 6789665 — intervention group
Group type: COMPARATOR
Intervention: Conventional regimen
Number of subjects: 18
Study 6789665 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study 31883251 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced Platelet-rich Fibrin (A-PRF)
Number of subjects: 10
Study 31883251 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 10
Study 27553058 — intervention group
Group type: EXPERIMENTAL
Intervention: Assigned weight label of 'overweight'
Number of subjects: 113
Study 26618505 — intervention group
Group type: EXPERIMENTAL
Intervention: GSM 900 MHz exposure
Number of subjects: 30
Study 26618505 — intervention group
Group type: EXPERIMENTAL
Intervention: WCDMA/UMTS exposure
Number of subjects: 30
Study 24918555 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin-Lidose
Number of subjects: 925
Study 24918555 — intervention group
Group type: COMPARATOR
Intervention: Food-dependent generic isotretinoin
Number of subjects: 925
Study 22124576 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 160
Study 19787809 — intervention group
Group type: EXPERIMENTAL
Intervention: Boceprevir (400 mg twice or three times daily for 14 days)
Number of subjects: 22
Study 19787809 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical modeling
Number of subjects: 22
Study 17287062 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact Model 730 automatic transport ventilator (Impact 730)
Number of subjects: 28
Study 17287062 — intervention group
Group type: COMPARATOR
Intervention: Conventional bag valve mask (BVM) ventilation
Number of subjects: 28
Study 15054653 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia (group A)
Number of subjects: 20
Study 15054653 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (group B)
Number of subjects: 20
Study 11575414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal midazolam with bupivacaine (BM1: 1 ml of 0.5% bupivacaine plus 0.2 ml of 0.5% midazolam)
Number of subjects: 45
Study 11575414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal midazolam with bupivacaine (BM2: 1 ml of 0.5% bupivacaine plus 0.4 ml of 0.5% midazolam)
Number of subjects: 45
Study 11575414 — intervention group
Group type: COMPARATOR
Intervention: Control group (1 ml of 0.5% heavy bupivacaine plus 0.2 ml of 0.9% saline)
Number of subjects: 45
Study 9849260 — intervention group
Group type: EXPERIMENTAL
Intervention: Three noncontact Therapeutic Touch treatments (15 to 20 minutes duration)
Number of subjects: 20
Study 9849260 — intervention group
Group type: COMPARATOR
Intervention: Three rest periods (Control group)
Number of subjects: 20
Study 7927447 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand sewn anastomosis (performed in two layers with 3/0 silk)
Number of subjects: 60
Study 7927447 — intervention group
Group type: COMPARATOR
Intervention: Stapled anastomosis (using EEA staplers)
Number of subjects: 60
Study 31782661 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care and person-centred care (PCC) in the form of structured telephone support, n=39
Number of subjects: 77
Study 31782661 — intervention group
Group type: COMPARATOR
Intervention: Usual care, n=38
Number of subjects: 77
Study 30214821 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 60
Study 30214821 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone plus antibiotics
Number of subjects: 60
Study 30214821 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant observation plus prednisolone
Number of subjects: 60
Study 30214821 — intervention group
Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 60
Study 30214821 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic alone
Number of subjects: 60
Study 28708678 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C
Number of subjects: 939
Study 28708678 — intervention group
Group type: COMPARATOR
Intervention: Targeted temperature management at 36°C
Number of subjects: 939
Study 28708678 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C or 36°C
Number of subjects: 939
Study 26289950 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-acquired medication history (MH) during admission to ED
Number of subjects: 270
Study 26289950 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no pharmacist-acquired MH)
Number of subjects: 270
Study 23108436 — intervention group
Group type: EXPERIMENTAL
Intervention: Core instability strength training (CIT) for 9 weeks
Number of subjects: 32
Study 21419314 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (WP) diet (40% carbohydrate/15% mixed protein/15% whey protein/30% fat)
Number of subjects: 18
Study 21419314 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (WP) diet
Number of subjects: 18
Study 21419314 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CD) (55% carbohydrate/15% protein/30% fat)
Number of subjects: 18
Study 21419314 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed protein diet (40% carbohydrate/30% protein/30% fat)
Number of subjects: 18
Study 19135415 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (0.75 mg) with dexamethasone (16 mg IV on day 1, followed by 8 mg IV for cisplatin or 4 mg orally for AC/EC on days 2 and 3)
Number of subjects: 1143
Study 19135415 — intervention group
Group type: COMPARATOR
Intervention: Granisetron (40 microg/kg) with dexamethasone (16 mg IV on day 1, followed by 8 mg IV for cisplatin or 4 mg orally for AC/EC on days 2 and 3)
Number of subjects: 1143
Study 19135415 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (0.75 mg) with dexamethasone
Number of subjects: 1143
Study 19135415 — intervention group
Group type: COMPARATOR
Intervention: Granisetron (40 microg/kg) with dexamethasone
Number of subjects: 1143
Study 17874980 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 80
Study 17874980 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 80
Study 14734594 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (starting dose 5 mg/d, increased to 20 mg/d, n = 203)
Number of subjects: 404
Study 14734594 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 201)
Number of subjects: 404
Study 12575607 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragalus Injection (AI) 40 ml (equivalent to 80 g crude drug) in 5% glucose solution 500 ml for intravenous dripping, once a day for 2 weeks
Number of subjects: 83
Study 12575607 — intervention group
Group type: COMPARATOR
Intervention: Nitrolingual injection 15 mg in 5% glucose solution 500 ml for intravenous dripping, once a day for 2 weeks
Number of subjects: 83
Study 9597024 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected diet with a goal of 15% of energy from fat
Number of subjects: 21
Study 8163713 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug with forced titration scheme
Number of subjects: 0
Study 8163713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8163713 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug (three arms with different maximum allowable doses)
Number of subjects: 0
Study 2894789 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcuronium 0.2 mg.kg‐1
Number of subjects: 28
Study 2894789 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium 0.08 mg.kg‐1
Number of subjects: 28
Study 31635538 — intervention group
Group type: EXPERIMENTAL
Intervention: Present-centered therapies for PTSD
Number of subjects: 141
Study 31635538 — intervention group
Group type: COMPARATOR
Intervention: Wait-list condition
Number of subjects: 141
Study 29808316 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab/Irinotecan (BEV/IRI)
Number of subjects: 142
Study 29808316 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (TMZ)
Number of subjects: 142
Study 27485267 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaxial technique
Number of subjects: 240
Study 27485267 — intervention group
Group type: COMPARATOR
Intervention: Noncoaxial technique
Number of subjects: 240
Study 26062108 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg E + 15 mg P (Group A)
Number of subjects: 84
Study 26062108 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg E + 20 mg P (Group B)
Number of subjects: 84
Study 26062108 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg E + 30 mg P (Group C)
Number of subjects: 84
Study 22961097 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 56
Study 22961097 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 56
Study 20353582 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-and-pencil at home via the mail
Number of subjects: 314
Study 20353582 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 314
Study 20353582 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-and-pencil at the hospital clinic
Number of subjects: 314
Study 20353582 — intervention group
Group type: COMPARATOR
Intervention: All modes of administration
Number of subjects: 314
Study 18431266 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 40
Study 18431266 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 40
Study 16891634 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg hyperbaric articaine hydrochloride (A60)
Number of subjects: 90
Study 16891634 — intervention group
Group type: EXPERIMENTAL
Intervention: 84 mg hyperbaric articaine hydrochloride (A84)
Number of subjects: 90
Study 16891634 — intervention group
Group type: EXPERIMENTAL
Intervention: 108 mg hyperbaric articaine hydrochloride (A108)
Number of subjects: 90
Study 12805327 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (intravenous mitomycin 1.33 mg/m2, fluorouracil 166.7 mg/m2, cytarabine 13.3 mg/m2 twice weekly for 3 weeks, followed by oral fluorouracil 134 mg/m2 daily for 18 months, total dose 67 g/m2)
Number of subjects: 252
Study 12805327 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 252
Study 10757249 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 17
Study 8855834 — intervention group
Group type: COMPARATOR
Intervention: Placebo, no exercise
Number of subjects: 43
Study 8855834 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE), no exercise
Number of subjects: 43
Study 8855834 — intervention group
Group type: COMPARATOR
Intervention: Placebo, exercise
Number of subjects: 43
Study 8855834 — intervention group
Group type: EXPERIMENTAL
Intervention: TE plus exercise
Number of subjects: 43
Study 1740582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragweed immunotherapy (IT)
Number of subjects: 53
Study 6514487 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis with suggestion to overcome displacement aftereffects (hypothesis informed)
Number of subjects: 50
Study 6514487 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow motion movement during posttest
Number of subjects: 50
Study 6514487 — intervention group
Group type: COMPARATOR
Intervention: Control group with no special instructions
Number of subjects: 50
Study 6514487 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothesis-informed group in Study 2
Number of subjects: 50
Study 6514487 — intervention group
Group type: COMPARATOR
Intervention: Control group in Study 2
Number of subjects: 50
Study 31575585 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections (BOTOX) at 8 UI/kg in the internal shoulder rotator muscles
Number of subjects: 62
Study 31575585 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure mimicking BTI
Number of subjects: 62
Study 31575585 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BTI and Sham)
Number of subjects: 62
Study 29705054 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroid therapy
Number of subjects: 38
Study 29705054 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nonsteroid group)
Number of subjects: 38
Study 27742246 — intervention group
Group type: EXPERIMENTAL
Intervention: 42-mm glenosphere
Number of subjects: 81
Study 27742246 — intervention group
Group type: COMPARATOR
Intervention: 38-mm glenosphere
Number of subjects: 81
Study 25449826 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) therapy
Number of subjects: 29
Study 22382037 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive strategy with periodic email prompts
Number of subjects: 9169
Study 22382037 — intervention group
Group type: COMPARATOR
Intervention: Control group (no email prompts)
Number of subjects: 9169
Study 20890791 — intervention group
Group type: EXPERIMENTAL
Intervention: Neodolpasse(®) Infusion Solution
Number of subjects: 120
Study 20890791 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline (placebo)
Number of subjects: 120
Study 17557933 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (prenatal education and home-based postpartum support)
Number of subjects: 0
Study 15084760 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate depot 3.75 mg once a month for 3 months and cyproterone acetate 300 mg once a week for 3 weeks (group A)
Number of subjects: 167
Study 15084760 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery without any pretreatment, group B)
Number of subjects: 167
Study 11553182 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (offspring of two parents with Type 2 diabetes)
Number of subjects: 42
Study 11553182 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (no family history of diabetes)
Number of subjects: 42
Study 11553182 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimum microvascular resistance
Number of subjects: 42
Study 9757854 — intervention group
Group type: COMPARATOR
Intervention: Nafarelin alone (200 microg intranasally twice daily)
Number of subjects: 43
Study 9757854 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin plus human parathyroid hormone‐(1‐34) (hPTH‐[1‐34]) (40 microg subcutaneously daily)
Number of subjects: 43
Study 8151606 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium (80 mmol/day) with fish oil (5 g of omega-3 fatty acids per day)
Number of subjects: 56
Study 8151606 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sodium (150 mmol/day) with fish oil
Number of subjects: 56
Study 8151606 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium with olive oil
Number of subjects: 56
Study 8151606 — intervention group
Group type: COMPARATOR
Intervention: Normal sodium with olive oil
Number of subjects: 56
Study 8151606 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 56
Study 8151606 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium restriction
Number of subjects: 56
Study 2470358 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (less than or equal to 2ng/kg/min)
Number of subjects: 210
Study 2470358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 31615294 — intervention group
Group type: EXPERIMENTAL
Intervention: Low health literacy
Number of subjects: 3459
Study 30714216 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-mm diameter fully covered self-expandable metal stent (FCSEMS)
Number of subjects: 202
Study 30714216 — intervention group
Group type: COMPARATOR
Intervention: 10-mm diameter fully covered self-expandable metal stent (FCSEMS)
Number of subjects: 202
Study 28115007 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 300
Study 28115007 — intervention group
Group type: COMPARATOR
Intervention: Home-based exercise education (Control)
Number of subjects: 300
Study 26894151 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 μg/kg + bupivacaine local infiltration + Dexemedetomidine infusion (Loading 0.5 μg/kg, Maintenance 0.2μg/kg/hr)
Number of subjects: 90
Study 26894151 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 μg/kg + bupivacaine local infiltration
Number of subjects: 90
Study 26894151 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 1 μg/kg
Number of subjects: 90
Study 24205786 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary therapy (CT)
Number of subjects: 32
Study 22124142 — intervention group
Group type: COMPARATOR
Intervention: TMS(CT)
Number of subjects: 8
Study 22124142 — intervention group
Group type: COMPARATOR
Intervention: SAS
Number of subjects: 8
Study 22124142 — intervention group
Group type: COMPARATOR
Intervention: TMS(SAS)
Number of subjects: 8
Study 22124142 — intervention group
Group type: COMPARATOR
Intervention: TMS+SAS
Number of subjects: 8
Study 19701925 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine with regular blood testing
Number of subjects: 0
Study 19701925 — intervention group
Group type: COMPARATOR
Intervention: Comparator treatments with limited blood testing
Number of subjects: 0
Study 17718365 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploration strategy 1
Number of subjects: 0
Study 17718365 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploration strategy 2
Number of subjects: 0
Study 17718365 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased angular extent from 20 degrees to 135 degrees
Number of subjects: 0
Study 17718365 — intervention group
Group type: EXPERIMENTAL
Intervention: Local apex information
Number of subjects: 0
Study 17718365 — intervention group
Group type: EXPERIMENTAL
Intervention: Depiction mode
Number of subjects: 0
Study 15562017 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol and inhibin secretion from ovarian follicles
Number of subjects: 49
Study 15562017 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular development in POF women
Number of subjects: 49
Study 15562017 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH levels in POF women
Number of subjects: 49
Study 15562017 — intervention group
Group type: COMPARATOR
Intervention: Comparison of FSH levels
Number of subjects: 49
Study 15562017 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibin levels in relation to FSH
Number of subjects: 49
Study 12386042 — intervention group
Group type: EXPERIMENTAL
Intervention: Case method learning dialogues facilitated by a cardiologist
Number of subjects: 255
Study 12386042 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional presentation of practice guidelines)
Number of subjects: 255
Study 10639657 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Achilles tendinosis
Number of subjects: 9
Study 10639657 — intervention group
Group type: COMPARATOR
Intervention: Normal Achilles tendons
Number of subjects: 9